Traders cheered fresh reporting on Friday that Washington is shaping rules that would probably permit American drugmakers to continue tapping Chinese partners for most new medicines. People familiar told Reuters the Treasury Department is drafting a framework that would likely allow investments in Chinese companies' promising drug candidates, except for projects tied to pathogens or to biotech with potential for weaponization. The report also flagged that nothing is final and the details could still change. If adopted, biopharma would be treated differently from hot-button areas like artificial intelligence and chips, where curbs on China have tightened.
The rally was broad. The Hang Seng Biotech Index rose more than 5% on the day. Gainers included Innovent Biologics, up 6%; Akeso, higher by 8%; CSPC Pharmaceutical Group, up more than 6%; HUTCHMED, ahead 3%; and Sino Biopharmaceutical, up 8%. For context, Akeso last traded at HKD 99.30, up HKD 8.80 or 9.72% at 4:08 PM CTT, with data delayed.
Deal flow between U.S. and Chinese drug developers has been thick. Reuters, citing GlobalData, noted that nearly half of U.S. licensing agreements for overseas drugs in 2025 involved Chinese counterparts. One marquee example: in May, Pfizer unveiled a collaboration with Innovent valued at up to $10.5 billion, spanning R&D for 12 oncology programs.
Despite geopolitics, China's out-licensing wave has not let up. Drawing on NMPA figures, Nomura reported that the first half of 2026 saw an all-time high of 81 transactions totaling $110 billion. The bank added that investors now seem "largely immune" to the sector's periodic political noise, pointing to the strong value proposition in China's novel drug development.
Opportunities in global healthcare innovation remind investors to balance growth with prudent protection. Join Briefs Finance CEO Jaspreet Singh on September 29th for a FREE live investor workshop, How to Profit From A Dollar That's Losing its Value, where he shows how we're spotting investment opportunities as the dollar falls. Save your spot.
For everyday investors, the takeaway is simple enough: policy signals can quickly reprice where drug money flows, and the most active partnerships are a useful map for where attention is building.
Keeping a steady plan helps you pursue gains while safeguarding long term savings. Our CEO Jaspreet Singh is hosting a FREE live investor workshop, How to Profit From A Dollar That's Losing its Value, on September 29th. Sign up free to join him live.
